Mesoblast Limited shares rose Monday after the company said it has reached a key enrollment milestone in its pivotal Phase 3 trial testing rexlemestrocel-L for chronic low back pain tied to inflammatory degenerative disc disease. The report came alongside a timetable toward mid-2027 for top-line results, keeping investor focus on the therapy’s confirmatory path following earlier trial data.
Mesoblast said the MSD-DR004 study has now treated at least 300 patients, matching the target number previously agreed with the U.S. Food and Drug Administration for a confirmatory Phase 3 program. The stock closed the session at $16.22, up 5.05%.
Key takeaways
- Price move: Mesoblast shares closed up 5.05% at $16.22.
- Catalyst: The company reported it has achieved treatment of at least 300 patients in the pivotal Phase 3 MSD-DR004 trial.
- What the trial tests: rexlemestrocel-L delivered via a single intradiscal injection combined with hyaluronic acid.
- Primary goal: Reduction in low back pain at 12 months versus sham controls.
- Implication: The milestone removes a major execution risk and keeps the company on track for mid-2027 top-line results.
What Mesoblast said about MSD-DR004
MSD-DR004 is designed as a multicenter, randomized, double-blind, placebo-controlled study. According to the company, participants were previously diagnosed with chronic low back pain caused by inflammatory degenerative disc disease with a duration of less than five years. Treatment is being delivered across multiple sites in the United States.
The therapy, rexlemestrocel-L, is an allogenic stromal cell treatment. Mesoblast noted that the FDA granted the program Regenerative Medicine Advanced Therapy (RMAT) designation for chronic low back pain, a status intended to support expedited development for regenerative medicine products that may address serious conditions and meet certain criteria.
Trial design and clinical endpoints
MSD-DR004 evaluates rexlemestrocel-L in combination with hyaluronic acid, administered as a single intradiscal injection. The primary endpoint is the change in low back pain at 12 months compared with sham controls, the company said.
Secondary endpoints include improvements in physical function and quality of life, alongside measures related to pain medication use, including reductions in or cessation of pain medications such as opioids. Investors typically track both pain outcomes and downstream functional measures, particularly in chronic pain indications where maintaining mobility and reducing reliance on stronger medications can influence perceived clinical value.
How the FDA engagement shaped the program
Mesoblast said the FDA previously agreed on the design of the confirmatory Phase 3 trial, including the 300-patient target, based on positive results from its earlier Phase 3 MSB-DR003 trial. The company expects MSD-DR004 to further confirm the therapy’s efficacy and safety profile.
From a regulatory perspective, confirmation trials are often used to validate earlier signals and establish consistency of outcomes across a broader population and study setting. Achieving the agreed-upon treatment number helps de-risk the likelihood that the study can meet its planned statistical power and endpoint assessment schedule.
What happens next for investors
Mesoblast expects to report top-line results for MSD-DR004 in mid-2027, after the last treated patient completes 12 months of follow-up. That timeline means the next major catalysts for investors will likely center on interim regulatory interactions, continued patient follow-up progress, and the eventual reporting of primary and secondary endpoints.
Investors will also watch how the company communicates any emerging safety signals as follow-up accrues and whether the trial data supports meaningful differences versus sham controls across both pain reduction and functional measures. With chronic low back pain already a highly competitive area for new treatments, the confirmatory readout in 2027 will be pivotal for clarifying the commercial and clinical trajectory of rexlemestrocel-L.
